Teijin Pharma to Launch Ipsen (IPN.PA)'s Somatuline® Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan  
1/17/2013 9:20:05 AM

TOKYO & PARIS--(BUSINESS WIRE)--Regulatory News: Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Ipsen (Euronext: IPN; ADR: IPSEY) (Paris:IPN), today announced the launch of Somatuline® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform). In Japan, Teijin Pharma holds the rights to develop and market the drug.